GlobalData on MSN1d
Gilead’s Livdelzi shows promise in PBC clinical trial
The analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
The Pharma Letter3d
Gilead’s Livdelzi reduced pruritus severity in PBC participants
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...
Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management
Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which ...
Morningstar4d
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Livdelzi Reduced Pruritus Severity in PBC Participants and Led to Near Resolution of Itch in 27% of Participants with Moderate to Severe Itch – Gilead Sciences, Inc. (Nasdaq: GILD)today ...
Business Insider18h
Gilead price target raised to $100 from $85 at Argus
The company ecently announced that the FDA granted accelerated approval for Livdelzi in combination with ursodeoxycholic acidfor the treatment of primary biliary cholangitis, the analyst tells ...
Nasdaq2d
Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management
Using a data cutoff of January 31, 2024, the interim analysis represented all participants in the ASSURE study, including those who participated in prior clinical studies of Livdelzi (legacy ...
Investing4d
Livdelzi shows promise in PBC treatment study
Gilead Sciences, Inc. (NASDAQ:GILD) today shared interim results from an ongoing Phase 3 ASSURE study, demonstrating that 81% of primary biliary cholangitis (PBC) patients treated with Livdelzi ...
Stockhouse4d
Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Livdelzi Reduced Pruritus Severity in PBC Participants and Led to Near Resolution of Itch in 27% of Participants with Moderate to Severe Itch – Gilead Sciences, Inc. (Nasdaq: GILD)today announced data ...
ADVFN4d
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
GILD Gilead Sciences Inc Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis ...
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...